tbuckley/cabot-search huggingface dataset:
Development and implementation of “advanced cancer shared care letters” to improve shared care between oncologists and family physicians.
Authors: Sharon Watanabe, Camille Bond, Amy Tan, Patricia A. Tang, Safiya Karim, Marc Kerba, Patricia Biondo, Jessica Simon, Aynharan Sinnarajah
Journal: Journal of Clinical Oncology (2019)

37 Background: Optimal care of patients living with advanced cancer requires a collaborative approach between oncologists and family physicians (FPs), starting early in the disease trajectory. We developed and implemented “advanced cancer shared care letters” to improve communication, collaboration and role clarity amongst providers. Methods: A physician-to-physician standardized “advanced cancer shared care letter” for colorectal cancer was created at a Canadian tertiary cancer center with input across stakeholders. The letter is ordered by the oncologist when they determine a patient to have advanced (i.e. incurable) cancer. The letter outlines components of shared care, division of responsibilities, monitoring for complications, responding to oncological emergencies, and consultation services such as palliative care. A cover sheet is provided for FPs to return to confirm their involvement, indicate their comfort level with providing a palliative approach to care (e.g. advance care planning, managing symptoms) and ask questions. Letters were piloted in two gastrointestinal (GI) oncology outpatient clinics for two months, and then implemented in the seven remaining GI clinics over two months. Metrics were collected for five months to evaluate implementation. Results: Over 5 months, 76 shared care letters were ordered; in 5 cases, no FP was identifiable. Cover sheets were returned by 39/71 FPs (55%). Content returned included prognosis questions, goals of care conversations, supportive services available in their practice and those in use by the patient, capacity to manage symptoms (e.g. opioid prescribing), and requests to engage palliative care services. Implementation challenges included frequent change in clerical staff and management, electronic chart challenges and variable adoption. Conclusions: The shared care letter provides a useful mechanism for FPs and oncologists to share information. It increases communication and care coordination between typically siloed providers, to enhance patient experience. A similar letter is provided to patients and we are now developing a shared care letter that is generalizable for any type of advanced cancer.
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia
Authors: Kathryn G. Roberts, Samuel W. Brady, Zhaohui Gu, Lei Shi, Stanley Pounds, Deqing Pei, Cheng Cheng, Yunfeng Dai, Meenakshi Devidas, Chunxu Qu, Ashley Hill, Xiaotu Ma, Lei Wei, Sasi Arunachalam, Kohei Hagiwara, Yangling Liu, Diane Flasch, Yu Liu, Matthew Parker, Xiaolong Chen, Yongjin Li, Yiping Fan, Robert Michael, Michael Rusch, Mark Wilkinson, Scott Foy, Dale Hedges, Scott Newman, Xin Zhou, Jian Wang, Shalini C. Reshmi, Julie M. Gastier-Foster, Patee Gesuwan, Malcolm A Smith, Daniela S. Gerhard, Naomi Winick, Andrew J. Carroll, Nyla A. Heerema, Richard C. Harvey, Cheryl L. Willman, Eric Larsen, Elizabeth A. Raetz, Michael J. Borowitz, Brent L Wood, William L. Carroll, Patrick A. Zweidler-McKay, Karen R. Rabin, Leonard A. Mattano, Kelly Maloney, Stuart S. Winter, Michael J. Burke, Wanda L. Salzer, Kimberly P. Dunsmore, Anne Angiolillo, Kristine R Crews, James R. Downing, Sima Jeha, William E. Evans, Ching-Hon Pui, Jun J. Yang, Mary V. Relling, Stephen P. Hunger, Mignon L. Loh, Jinghui Zhang, Charles G. Mullighan
Journal: Blood (2019)
Explaining historical change in terms of LHT: A pluralistic causal framework is needed
Authors: Aurélien Allard, Antoine Marie
Journal: Behavioral and Brain Sciences (2019)

Baumard suggests that the advent, through phenotypic plasticity mechanisms, of future-oriented preferences and creative mindsets in eighteenth-century Great Britain explains the wave of innovations that drove the British Industrial Revolution. We argue that, although this approach is promising, Baumard's model would benefit from being supplemented by demographic, economic, and sociological explanations independent of Life History Theory (LHT).
Absence of Autoantibodies Against Neuronal Surface Antigens in Sera of Patients With Psychotic Disorders
Authors: Carolin Hoffmann, Shenghua Zong, Marina Mané-Damas, Peter C. Molenaar, Mario Losen, Maarten J. Titulaer, Pilar Martinez-Martinez
Journal: JAMA Psychiatry (2019)

Absence of Autoantibodies Against Neuronal Surface Antigens in Sera of Patients With Psychotic DisordersPatients with antibodies against neuronal surface antigens (NSAbs), including the N-methyl-D-aspartate receptor (NMDAR), typically develop autoimmune encephalitis with characteristic neurological and psychiatric symptoms. 1In 4% of individuals with NMDAR encephalitis, isolated psychotic episodes occur without simultaneous neurological involvement. 2This raises the question of whether NSAbs are underdiagnosed in patients with psychotic disorders.Results of studies testing this, however, are contradictory, [3][4][5] possibly because of differences in the methods of antibody detection.Previously, in a cohort of 475 patients with schizophrenia, we found no one with NMDAR antibodies after excluding 2 false-positive results by combined immunohistochemistry (IHC) tests and cell-based assays (CBAs) across laboratories. 6 In this analysis, we extend these studies to other common NSAbs known to cause encephalitis, aiming to expand the clinical spectrum of psychosis potentially caused by autoantibodies. Methods |The cohort included individuals with psychotic disorders, who were further divided into those with schizophrenia, schizoaffective disorder, brief psychotic disorder, and firstepisode psychosis diagnoses (as defined by the DSM-IV), and control participants (Table ).Samples from all participants were screened by IHC testing for immunoreactivity to rat hippo-
Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells
Authors: Aneel Paulus, Alak Manna, Sharoon Akhtar, Taimur Sher, Vivek Roy, Morton Coleman, Anne J Novak, Stephen M Ansell, Fabio Malavasi, Sikander Ailawadhi, Asher A. Chanan-Khan
Journal: Blood (2017)
G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action
Authors: Stacy Gelhaus Wendell, Hao Fan, Cheng Zhang
Journal: Pharmacological Reviews (2019)

Asthma is a heterogeneous inflammatory disease of the airways that is associated with airway hyperresponsiveness and airflow limitation. Although asthma was once simply categorized as atopic or nonatopic, emerging analyses over the last few decades have revealed a variety of asthma endotypes that are attributed to numerous pathophysiological mechanisms. The classification of asthma by endotype is primarily routed in different profiles of airway inflammation that contribute to bronchoconstriction. Many asthma therapeutics target G protein–coupled receptors (GPCRs), which either enhance bronchodilation or prevent bronchoconstriction. Short-acting and long-acting <i>β</i><sub>2</sub>-agonists are widely used bronchodilators that signal through the activation of the <i>β</i><sub>2</sub>-adrenergic receptor. Short-acting and long-acting antagonists of muscarinic acetylcholine receptors are used to reduce bronchoconstriction by blocking the action of acetylcholine. Leukotriene antagonists that block the signaling of cysteinyl leukotriene receptor 1 are used as an add-on therapy to reduce bronchoconstriction and inflammation induced by cysteinyl leukotrienes. A number of GPCR-targeting asthma drug candidates are also in different stages of development. Among them, antagonists of prostaglandin D<sub>2</sub> receptor 2 have advanced into phase III clinical trials. Others, including antagonists of the adenosine A<sub>2B</sub> receptor and the histamine H4 receptor, are in early stages of clinical investigation. In the past decade, significant research advancements in pharmacology, cell biology, structural biology, and molecular physiology have greatly deepened our understanding of the therapeutic roles of GPCRs in asthma and drug action on these GPCRs. This review summarizes our current understanding of GPCR signaling and pharmacology in the context of asthma treatment. <h3>SIGNIFICANCE STATEMENT</h3> Although current treatment methods for asthma are effective for a majority of asthma patients, there are still a large number of patients with poorly controlled asthma who may experience asthma exacerbations. This review summarizes current asthma treatment methods and our understanding of signaling and pharmacology of G protein<b>–</b>coupled receptors (GPCRs) in asthma therapy, and discusses controversies regarding the use of GPCR drugs and new opportunities in developing GPCR-targeting therapeutics for the treatment of asthma.
Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)
Authors: Diego Adrianzen Herrera, Kith Pradhan, Rosebella Snyder, Siddharth Karanth, Murali Janakiram, Ioannis Mantzaris, Santosh Murthy, Amit Verma, Aditi Shastri
Journal: Blood (2019)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Authors: Naval G. Daver, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Nikolaos Papadantonakis, Eric Deconinck, Harry P. Erba, Naveen Pemmaraju, Andrew A. Lane, David A. Rizzieri, Kendra L. Sweet, Giovanni Martinelli, Corrado Tarella, Elisabetta Todisco, Marina Y Konopleva, Callum M. Sloss, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, Hagop M. Kantarjian
Journal: Blood (2019)
Epidemiology, molecular, and genetic methodologies to evaluate causes of CKDu around the world: report of the Working Group from the ISN International Consortium of Collaborators on CKDu
Authors: Shuchi Anand, Ben Caplin, Marvin Gonzalez-Quiroz, Stephen L. Schensul, Vivek Bhalla, Xavier Parada, Nishantha Nanayakkara, Andrew Fire, Adeera Levin, David J. Friedman, Angie Aguilar-Gonzalez, Kevin Abbot, Thilak Abeysekara, Kerstin Amann, Shuchi Anand, Gloria Ashuntantang, Vivek Bhalla, Daniel Brooks, Ben Caplin, Denis Chavarria, Daniel Christoph, Ricardo Correa Rotter, Marc De Broe, P. Mangala C.S. De Silva, Jose Dominguez, Kai-Uwe Eckardt, Dorien Fader, Fred Finkelstein, Andrew Fire, Rebecca Fischer, David Friedman, Anirban Ganguli, Ramon Antonio Garcia Trabinho, Jason Glaser, Marvin Antonio Gonzalez Quiroz, Rebecca Fischer, Lalarukh (Lali) Haider, David Harris, Chulani Herath, Raul Herrera, Anne Hradsky, Wendy Hoy, Kristina Jakobsson, Saroj Jayasinghe, Channa Jaysummana, Vivek Jha, Richard Johnson, Neeraja Kambham, Nishamani Karanasema, Francois Kaze, Paul Kimmel, Erik Koritzinsky, Robyn Langham, Laurent Le Bellego, Adeera Levin, Nathan Levin, Valerie Lyuckx, Magdalena Madero, Ekiti Martin, Charu Malik, Louise Moist, Marva Moxey-Mims, Nishantha Nanayakkara, Andrew Narva, Fabiana Nerbass, Donal O'Donoghue, Carlos Orantes, Xavier Parada, Neil Pearce, Charaka Ratnayake, Prabheer Roy-Chaudhury, Agnese Ruggiero, Laura Gabriela Sanchez-Lozada, Rajiv Saran, Stephen Schensul, Luca Segantini, Isabelle Seksek, David Sheikh-Hamad, Robert Star, Luisa Strani, Penny Vlahos, David H. Wegman, Ilana Weiss, Eranga Wijewickrama, Julia Wijkstrom, Paul Wise, Emily Wright, Chih-Wei Yang, Karen Yeates
Journal: Kidney International (2019)
Green tea polyphenol EGCG antagonizes androgen function: Novel insight into the mechanism of chemopreventive effects of green tea on prostate cancer
Authors: Mohammad Asim, Bilal Bin Hafeez, Imtiaz Siddiqui, Hasan Mukhtar
Journal: Cancer Research (2008)

2107  Oral consumption of green tea polyphenols containing epigallocatechin-3-gallate (EGCG) to TRAMP and other mouse models affords substantial prostate cancer (PCa) chemo-preventive effects. Epidemiological and clinical studies indicate that these animal data are also applicable to human PCa patients. Androgens play a central role in prostate development and PCa proliferation. Androgen receptor (AR) manifests the biological actions of androgens. AR activity is critical for PCa progression and its transactivation is known to enhance PCa cell survival. AR is known to act as a homodimer on the regulatory elements of the target genes to modulate their expression and the interdomain interaction (N-C terminus interaction) of AR is required for the optimal/maximal activation of the receptor. Since the growth of prostate cancer cells is regulated by androgens, we hypothesized that EGCG will blunt AR function in PCa. We first asked whether EGCG can act as a ligand for AR. EGCG was therefore screened in AR competitive binding assay employing time-resolved fluorescence resonance energy transfer (TR-FRET) format where ligands for AR are identified by their ability to compete with and displace fluorescent dihydrotestosterone (DHT) from the receptor. EGCG was found to compete and displace fluorescent DHT and disrupted FRET, resulting in a lower TR-FRET ratio with an effective IC50 of 0.4 µM. To evaluate the functional consequence of this interaction on transcription activation function of AR, a reporter assay was performed to determine how EGCG modulates hormone-dependent AR action. We observed that in LNCaP cells, EGCG led to a dose-dependent decrease in AR transcription activation function on a cognate reporter element MMTV containing AR binding sites. This indicates that physical interaction of EGCG with AR leads to attenuation of its transactivation function implicating EGCG to be a novel antagonist of AR function. To further explain decrease in AR transactivation, an interdomain interaction assay was performed which clearly indicated a decrease in AR amino-carboxy termini interaction by EGCG. Since AR transactivation is known to positively stimulate growth of PCa cells and EGCG led to a potent inhibition of this function, next we tested the effect of EGCG on the growth of hormone R1881 stimulated PCa LNCaP cells employing MTT assay. R1881 treatment enhanced cell growth and this enhancement was blunted by EGCG. Taken together, we propose EGCG as a novel candidate antagonist of AR signaling in PCa that may function as a PCa chemotherapeutic agent alone or in combination with currently employed chemotherapeutic regimens.
Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study
Authors: Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans Hasselbalch, Robert Kralovics, Heinz Gisslinger
Journal: Blood (2019)
Establishment of Best Practices for Evidence for Prediction
Authors: Russell A. Poldrack, Grace Huckins, Gael Varoquaux
Journal: JAMA Psychiatry (2019)

<h3>Importance</h3> Great interest exists in identifying methods to predict neuropsychiatric disease states and treatment outcomes from high-dimensional data, including neuroimaging and genomics data. The goal of this review is to highlight several potential problems that can arise in studies that aim to establish prediction. <h3>Observations</h3> A number of neuroimaging studies have claimed to establish prediction while establishing only correlation, which is an inappropriate use of the statistical meaning of prediction. Statistical associations do not necessarily imply the ability to make predictions in a generalized manner; establishing evidence for prediction thus requires testing of the model on data separate from those used to estimate the model's parameters. This article discusses various measures of predictive performance and the limitations of some commonly used measures, with a focus on the importance of using multiple measures when assessing performance. For classification, the area under the receiver operating characteristic curve is an appropriate measure; for regression analysis, correlation should be avoided, and median absolute error is preferred. <h3>Conclusions and Relevance</h3> To ensure accurate estimates of predictive validity, the recommended best practices for predictive modeling include the following: (1) in-sample model fit indices should not be reported as evidence for predictive accuracy, (2) the cross-validation procedure should encompass all operations applied to the data, (3) prediction analyses should not be performed with samples smaller than several hundred observations, (4) multiple measures of prediction accuracy should be examined and reported, (5) the coefficient of determination should be computed using the sums of squares formulation and not the correlation coefficient, and (6) k-fold cross-validation rather than leave-one-out cross-validation should be used.
Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Authors: H. Lin, W. Ran, X. Chen, B. Wang, P. Yang, Y. Li, Y. Xiao, X. Wang, G. Li, L. Wang, Y. Han, Y. Peng, J. Lang, Y. Liang, G. Tian, D. Yuan, J. Yang, C. Deng, X. Xing
Journal: Annals of Oncology (2019)
The effect of coaching-based lay patient navigation on patient satisfaction and overcoming barriers to care.
Authors: Dawn Wiatrek, Nicole Erb, Shelby Roberts
Journal: Journal of Clinical Oncology (2019)

36 Background: The American Cancer Society is enhancing its lay patient navigator program to include tailored coaching in addition to resource navigation. The goal is to increase the patient’s engagement in overcoming barriers to care. In a pilot of this new model, 6 navigators in 6 different program sites completed a training in coaching, active listening and action planning with patients. Methods: A total of 1,210 patients were navigated through the pilot program over 2 phases. This abstract focuses on phase 2 consisting of 792 patients navigated by 3 navigators at 3 different safety-net hospitals. The navigators met with patients over a 1-year period and engaged in coaching sessions to set action plans to overcome barriers to care. In the first session, navigators developed an action plan with the patient and administered a patient satisfaction survey. Over time, the navigators continued meeting with the patient and documenting progress on the action plan. Navigators administered a second patient satisfaction survey prior to or during the patient's last session. Results: 792 patients had a first coaching session with the navigator and set a combined 2,430 actions to overcome 1,356 barriers. 87% of patients agreed to take the first patient satisfaction survey with 95% reporting that they created a plan with the navigator. Patients reported an average confidence level of 8.6/10 that the plan they set with the navigator would work. Patients also reported a high level of satisfaction with the meeting with an average score of 4.4 on a 5-point scale. 408 patients completed the full coaching program during the project period and 77% of those patients with a final coaching session completed the satisfaction survey. 88% of patients reported completing at least some steps in their action plan and 89% reported solving at least one problem with the navigator that came up during their cancer care. Overall satisfaction with the navigator remained constant at 4.4/5. Conclusions: Patients responded positively to coaching-based lay patient navigation and were able to create action plans with the navigator, achieve those actions, and ultimately overcome non-medical barriers to cancer care.
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
Authors: Kwee Yong, Rakesh Popat, William Wilson, Gavin Pang, Richard Jenner, Ruth M De Tute, Karthik Ramasamy, Matthew Streetly, Jamie Cavenagh, Jonathan Sive, Michael Chapman, Ceri Bygrave, Beth Phillips, Selina J Chavda, Andres E. Virchis, Reuben Benjamin, Sarah Arnott, Fenella Willis, Sandra Hassan, Sally Moore, Laura Clifton-Hadley, Roger G Owen
Journal: Blood (2019)
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
Authors: Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor Gallagher, Yan Liu, Gill Shears, Roman G. Rubio
Journal: Journal of the American Academy of Dermatology (2019)

DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development. Phase 2 data have shown it offers a more prolonged duration of response than onabotulinumtoxinA.To further evaluate the efficacy, duration of response, and safety of 40 U DAXI compared with placebo in the treatment of glabellar lines.Two identical, multicenter, randomized, double-blind, placebo-controlled, phase 3 studies were performed (NCT03014622 and NCT03014635 on www.clinicaltrials.gov). Participants with moderate or severe glabellar lines were randomly assigned (2:1) to receive 40 U DAXI or placebo into the corrugator/procerus muscles. Glabellar line severity was assessed by investigators and participants for up to 36 weeks (≥24 weeks).Among 609 participants enrolled (405 DAXI, 204 placebo), 92% completed. DAXI was significantly more effective than placebo in reducing glabellar line severity and maintained none or mild glabellar line severity for a median of 24.0 weeks. It was also generally well tolerated-treatment-related adverse effects were most commonly headache (6.4% vs 2.0%) and injection site pain (3.7% vs 3.9%).The study population was predominantly female and white and received only a single treatment.DAXI offers a prolonged duration of response for glabellar line reduction and is well tolerated.
Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial
Authors: Brian Kornblit, Barry Storer, Michael B. Maris, Niels Smedegaard Andersen, Thomas R. Chauncey, Effie W. Petersdorf, Ann Woolfrey, David G. Maloney, Rainer Storb, Brenda M Sandmaier
Journal: Blood (2019)
Different Biomarker Modalities and Response to Anti–PD-1/PD-L1 Therapies—Reply
Authors: Steve Lu, Hao Wang, Janis M. Taube
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal